Funding
Funding not disclosed
Founders
Product
Problem
Current cancer diagnostics often rely on limited genetic panels or pathology reports that miss many actionable molecular alterations, leading to suboptimal treatment selection for patients with heterogeneous tumors.
Solution
Valius Sciences offers a maximal molecular profiling service that comprehensively analyzes a tumor across DNA, RNA, and protein layers. By integrating whole-genome sequencing, transcriptomics, high-plex protein assays, and spatial/immune profiling, the platform uncovers actionable targets, driver mutations, and tumor heterogeneity that standard tests overlook. Proprietary bioinformatic pipelines compare each tumor to thousands of reference samples, identifying similar cases and pathway activations to inform therapeutic prioritization. Results are delivered through an interactive, AI‑enhanced portal that remains accessible to patients and their care teams for ongoing query and interpretation, supported by regular consultations with Valius scientists.
Target Audience
Primary customers are oncology clinics, academic medical centers, and pharmaceutical partners seeking detailed molecular insights to guide personalized cancer therapy for their patients.
Features
- Whole-genome sequencing combined with ultra-sensitive ctDNA analysis for comprehensive genomic coverage
- Deep RNA sequencing, including bulk, single‑cell, and spatial transcriptomics, to assess gene expression and pathway activation
- High‑plex protein profiling to quantify target protein levels and immune microenvironment composition
- Bioinformatic comparison against large reference cohorts to highlight similar tumor profiles and potential treatment options
- AI‑driven, queryable data platform that provides perpetual access to results and enables custom analyses
- Dedicated scientific support with regular meetings to contextualize findings and guide therapeutic decisions